NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

A Phase 1 Dose-Escalation Study of NPX372, a Bispecific Antibody Targeting B7-H7 and CD3, in Selected Solid Tumor Malignancies

NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer cells with B7-H7.

In this research study we are:

• Evaluating the safety and possible effectiveness of NPX372.
• Identifying a safe and tolerable dose or doses for further study.

Participants who are treated will receive an intravenous (IV) infusion of NPX372 if their disease has not progressed, and be closely monitored by the treating physicians.

Study Overview

• Status: Not yet recruiting
• Conditions: Metastatic Malignant Neoplasm
• Intervention / Treatment: Drug: NPX372

Detailed Description

NPX372 is being developed as a therapeutic in solid tumor malignancies including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), pancreatic adenocarcinoma (PDAC), biliary tract tumors, ovarian carcinoma, and gastric/gastro-esophageal carcinoma. This study is a Phase 1 study with primary dose-escalation occurring in the aforementioned solid tumor malignancies (main cohorts). Backfill cohorts from a selected subset of these tumor types will be utilized to enrich for dose optimization in participants whose tumors have high B7-H7 expression determined by prospective screening of archival tissue.

• Study Type: Interventional
• Enrollment (Estimated): 81
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Trials nextpointtx; Phone Number: (508) 214-1115; Email: NPX372-001@nextpointtx.com

Study Locations

• United States
  • California
    • La Jolla, California, United States, 92093
      • University of California - San Diego
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Johns Hopkins
  • New York
    • The Bronx, New York, United States, 10461
      • Montefiore
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Sarah Cannon Research Institute
  • Texas
    • Houston, Texas, United States, 77030
      • MD Anderson Cancer Center
  • Virginia
    • Fairfax, Virginia, United States, 22031
      • NEXT

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

INCLUSION CRITERIA:

• Ability to understand and the willingness to sign a written informed consent document.
• Histologically or cytologically confirmed recurrent or metastatic solid tumor refractory to standard of care therapy in one of the following indications: NSCLC, RCC, CRC, PDAC, biliary tract tumors, gastric and gastro-esophageal carcinoma, and ovarian carcinoma.
• Measurable disease by RECIST v1.1 criteria.
• Age ≥19 years.

• Adequate organ function as defined by:

  • Calculated creatinine clearance (CrCl) must be ≥45 mL/min (by Cockroft-Gault formula).
  • Total bilirubin ≤1.5× the upper limit of normal (ULN) unless prior history of Gilbert's syndrome who must have total bilirubin <3.0 mg/dL.
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5× ULN, or ≤5× ULN if due to liver involvement by tumor.
  • Serum albumin ≥3.0 g/dL.
  • Hemoglobin ≥9.0 g/dL, limited transfusion to reach this value may be allowed after discussion with the Sponsor's Medical Monitor.
  • Platelets ≥100 × 109 cells/L.
  • Absolute neutrophil count ≥1.5 ×109 cells/L.
  • Baseline oxygen saturation > 90% on room air

• All participants will be required to have sufficient archival tissue available. For backfill cohort participants, archival tissue will be used to confirm B7-H7 expression for enrollment (see inclusion criterion 2) during pre-screening.

  -If 3 participants are already enrolled in any backfill cohort, subsequent participants will be required to have a fresh biopsy during the screening period. These participants should therefore only be selected if judged safe to undergo a fresh biopsy.

• Male participants with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the trial starting with the Screening visit through 60 days after the last dose of study drug is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.

EXCLUSION CRITERIA:

• Prior treatment toxicity not resolved to grade 1 or below including any:

  • Systemic anti-cancer treatment: exceptions include alopecia, chronic stable neuropathy for >4 months, change in skin pigmentation, grade 2 anemia, or requiring replacement therapy for endocrine abnormalities (in this setting, symptoms should have resolved to grade 1 or below). Systemic anti-cancer treatment within 10 days prior to start of study is not allowed.
  • Limited-field radiotherapy: radiation therapy within 7 days prior to start of study or extended-field thoracic radiotherapy within 8 weeks of the first dose of study drug is not allowed.
  • Major surgery: major surgery (excluding placement of catheters, vascular access, or biopsy) within 4 weeks of the first dose of study drug is not allowed.
• Clinically or radiographically unstable brain metastases: Participants with known brain metastases should be clinically stable and asymptomatic. Participants with a history of brain metastases should have an MRI during screening. For participants who are noted to have new or enlarging brain metastases during screening, treatment with stereotactic radiosurgery (SRS) is permitted with the standard limited field radiotherapy washout of >7 days. Participants requiring more extensive radiation (ie, fractionated stereotactic radiation or whole-brain radiation) would need a washout period of ≥4 weeks. Participants should be off corticosteroids for central nervous system (CNS) treatment for at least 7 days prior to dosing.
• Cardiac conditions as follows: history of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification; cardiac arrhythmias >Grade 2, unstable angina, coronary/peripheral artery bypass graft within 3 months, or evidence of 2nd- or 3rd-degree heart block.

• Uncontrolled intercurrent illness including, but not limited to, uncompensated respiratory, cardiac, hepatic, or renal disease, active infection (including hepatitis B virus [HBV], hepatitis C virus [HCV], human immunodeficiency virus [HIV] infections except as below, and active clinical tuberculosis), or renal transplant; ongoing or active infection, or social situations that would limit compliance with study requirements.

  • HIV: Seropositive participants without an acquired immunodeficiency syndrome (AIDS) defining illness and those with AIDS defining conditions on anti-retroviral therapy (ART) are eligible if they are healthy and have a CD4 count >350 cells/mm3 at the time of screening (Day ≤28 days). Participants on ART must have HIV RNA levels <50 copies/mL or the lower limit of quantification (LLOQ) using a local assay at the time of screening. Participants on ART must have been on a stable regimen without dose modification for at least 4 weeks prior screening.
  • HBV: Participants with HBsAg positivity are eligible if they have undetectable viral load and have received HBV anti-viral therapy for at least 4 weeks prior to screening.
  • HCV: Participants with a history of HCV infection are eligible if they have undetectable HCV viralload at screening and have completed curative therapy >4 weeks prior to screening.
• Any evidence of hemoptysis or gastrointestinal (GI) bleeding within the last 3 months prior to screening.
• Known autoimmune disease requiring immunosuppressive treatment requiring the equivalent of more than 10 mg prednisone daily.
• History of unresolved prior immune-related toxicity except for endocrine abnormalities requiring replacement therapy or vitiligo.
• Prior treatment with a cytokine therapy or cytokine fusion therapy.
• History of prior or concomitant malignancy that requires other active treatment except for prostate cancer without radiographic evidence of disease on long-term androgen deprivation therapy for >6 months (ie, leuprolide).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: NPX372; NPX372 is provided in single-use 5 mg vials at 1 mg per mL and is administered as an IV infusion over 60 minutes.

Drug: NPX372; NPX372 is administered by IV infusion. The first cycle will be 3 weeks long and NPX372 will be given on the first day and one week later during this 3-week period. For most dose levels, the first day's dose (C1D1) will be a lower dose, which will serve as a "priming dose". The full dose will start on the second dose. After the first two doses, NPX372 will be administered every other week for up to 6 months. After that time, NPX372 will be given about once a month. Treatment may continue for up to 2 years as long as the patient is deriving benefit.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Dose Limiting Toxicity (DLT)	Number of participants with DLT	From first dose through 21 days
Overall incidence of Dose Limiting Equivalent Toxicity (DLET) during treatment	Number of participants with DLET	From first dose up to 24 months
Incidence of AEs, characterized overall and by type, seriousness, relationship to NPX372, and severity.	Number and type of AEs categorized by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	From first dose up to 24 months
Number of participants with abnormal laboratory parameters, vital signs, electrocardiogram (ECG) parameters, physical examination findings as characterized by type, frequency, timing, relationship to NPX372, and severity		From first dose up to 24 months
Drug discontinuation, drug interruptions/delays and dose reductions due to treatment-related AEs	Number of participants with changes to their dosing schedule as a result of treatment-related AEs	From first dose up to 24 months
Number of participants with AEs, DLTs (inclusive of DLETs), and PD changes within blood		From first dose up to 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	ORR: the proportion of participants with best overall response, i.e., complete response (CR) or partial response (PR), per RECIST 1.1	Up to 2 years or until progressive disease, death, unacceptable toxicity, participant withdraw consent or investigator's decision, whichever occurs first
Duration of Response (DOR)	DOR: the time interval from first occurrence of a documented objective response to the time of disease progression as determined by the Investigator using RECIST 1.1 or death from any cause, whichever comes first.	Up to 2 years or until progressive disease, death, unacceptable toxicity, participant withdraw consent or investigator's decision, whichever occurs first
Disease Control Rate (DCR)	DCR: the proportion of participants with a best ORR + Stable Disease (SD)	Up to 2 years or until progressive disease, death, unacceptable toxicity, participant withdraw consent or investigator's decision, whichever occurs first]
Progression-Free Survival (PFS)	PFS: the duration from the start of treatment until tumor progression or death of any cause	Up to 2 years or until progressive disease, death, unacceptable toxicity, participant withdraw consent or investigator's decision, whichever occurs first
NPX372 serum PK (Cmax)	Cmax - measurement of highest NPX372 plasma concentration over time	Following dose on Day 1 for Cycle 1 (21 days). Following dose on Day 1 for Cycles 2 through 7 (28 days). Following dose on Day 1 every 3 cycles up to the end of treatment and 90-day follow-up after Cycle 7 (28 days)
NPX372 serum PK (AUC0-last)	AUC-last: measurement of total NPX372 plasma concentration over time	Following dose on Day 1 for Cycle 1 (21 days). Following dose on Day 1 for Cycles 2 through 7 (28 days). Following dose on Day 1 every 3 cycles up to the end of treatment and 90-day follow-up after Cycle 7 (28 days)
NPX372 serum PK time of Cmax (Tmax)	Tmax - time to NPX372 maxiumum plasma concentration	Following dose on Day 1 for Cycle 1 (21 days). Following dose on Day 1 for Cycles 2 through 7 (28 days). Following dose on Day 1 every 3 cycles up to the end of treatment and 90-day follow-up after Cycle 7 (28 days)
NPX372 serum PK terminal half-life (T1/2)	T1/2 - measurement of the clearance of NPX372 from plasma over time	Following dose on Day 1 for Cycle 1 (21 days). Following dose on Day 1 for Cycles 2 through 7 (28 days). Following dose on Day 1 every 3 cycles up to the end of treatment and 90-day follow-up after Cycle 7 (28 days)
Degree of accumulation, incidence, and magnitude of ADA	Number of participants with anti-drug antibodies (ADA)	Following dose on Day 1 for Cycle 1 (21 days). Following dose on Day 1 for Cycles 2 through 7 (28 days). Following dose on Day 1 every 3 cycles up to the end of treatment and 90-day follow-up after Cycle 7 (28 days)
Overall Survival (OS)	Average length of survival for treated participants	From first dose until death from any cause through 24 months

Collaborators and Investigators

• Sponsor: NextPoint Therapeutics, Inc.
• Investigators: Study Director: Leena Gandhi, MD, Ph.D., NextPoint Therapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2026
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): July 1, 2027

Study Registration Dates

• First Submitted: March 30, 2026
• First Submitted That Met QC Criteria: April 30, 2026
• First Posted (Actual): May 4, 2026

Study Record Updates

• Last Update Posted (Actual): May 4, 2026
• Last Update Submitted That Met QC Criteria: April 30, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: solid tumor; bispecific antibody; dose escalation; CD3; HHLA2; B7-H7; T-cell engaging
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Neoplastic Processes; Pathological Conditions, Signs and Symptoms; Neoplasm Metastasis
• Other Study ID Numbers: NPX372-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No